Changes in Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study
EscaFlor
Changes in Cutaneous, Digestive and Urinary Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study
2 other identifiers
observational
55
1 country
4
Brief Summary
The main objective of this study is to characterize the evolution (over a period of 28 days) of superficial and deep bacterial skin flora in patients with stage 3 or 4 sacral pressure ulcers (bedsores). Changes in terms of pathogenic, potentially pathogenic and non-pathogenic bacterial species at the intra-individual and population levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2015
Typical duration for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 4, 2014
CompletedFirst Posted
Study publicly available on registry
February 5, 2014
CompletedStudy Start
First participant enrolled
May 11, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 21, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 21, 2017
CompletedJanuary 30, 2020
January 1, 2020
2.4 years
February 4, 2014
January 29, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples
At the individual level
Baseline (day 0)
List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples
At the individual level
Day 28
Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples
Calculated over the entire study population
baseline (day 0)
Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples
Calculated over the entire study population
Day 28
Secondary Outcomes (6)
Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.
baseline (Day 0)
Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.
Day 28
List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples
baseline (day 0)
List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples
Day 28
List of pathogenic, potentially pathogenic and commensal bacterial species in urine samples
baseline (day 0)
- +1 more secondary outcomes
Study Arms (1)
The study population
The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur. For a description of the study population, see the inclusion/exclusion criteria. Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample
Interventions
Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)
Eligibility Criteria
The study population consists of patients hospitalized in the Propara neurological rehabilitation (Montpellier, France) having at least one stage 3 or 4 bedsore in the pelvic region.
You may qualify if:
- The patient was correctly informed about study implementation, its objectives, constraints and patient rights
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is available for 28 days of follow-up
- The patient has one or more pelvic pressure ulcers (bedsores)(stage 3 or 4 only). Note: Patients with bedsores of varying stage will be included for the wound corresponding to the highest stage. If the patient has multiple bedsores of the same stage, the deepest wound will be selected.
- The patient requires a modern wound dressings (i.e. not tulle or gauze) without added bactericidal or antibiotic elements
- The patient is hospitalized ant the Propara neurological rehabilitation center (Montpellier, France)
- The patient has not received antibiotics in the last 14 days.
You may not qualify if:
- The patient is participating in another study, or has participated in another study in the last 3 months
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is pregnant, parturient, or breastfeeding
- The patient is already included in the present study
- The patient has sacral pressure ulcers of only stages 1 or 2, or does not have a sacral pressure ulcer
- Patient under curative anticoagulation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Centre Mutualiste Neurologique Propara
Montpellier, 34090, France
Laboratoire d'Etude et de Recherche en Environnement et Santé, Unité Biodiagnostic, UNIMES
Nîmes, 30000, France
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
Unité U1047 "Bacterial virulence and infectious diseases", UFR de Médecine
Nîmes, 30908, France
Related Publications (1)
Fayolle M, Morsli M, Gelis A, Chateauraynaud M, Yahiaoui-Martinez A, Sotto A, Lavigne JP, Dunyach-Remy C. The Persistence of Staphylococcus aureus in Pressure Ulcers: A Colonising Role. Genes (Basel). 2021 Nov 25;12(12):1883. doi: 10.3390/genes12121883.
PMID: 34946833DERIVED
Biospecimen
Bedsore superficial (swabbing) and deep (punch biopsies) samples are retained; stool and urine samples are retained. DNA extraction is aimed at describing microbial communities.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Catherine Dunyach-Remy, PhD
Centre Hospitalier Universitaire de Nîmes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 4, 2014
First Posted
February 5, 2014
Study Start
May 11, 2015
Primary Completion
September 21, 2017
Study Completion
September 21, 2017
Last Updated
January 30, 2020
Record last verified: 2020-01